Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B
HAMDAN MEDICAL JOURNAL · 2014
DOI: 10.7707/hmj.401 ↗Kurz gefasst
Fachartikel in der Zeitschrift HAMDAN MEDICAL JOURNAL, 2014. Verfasst von Gilles Gosselin.
Abstract (Originalsprache)
A unique series of simple synthetic L -enantiomer nucleosides had been shown by our former laboratories to inhibit hepatitis B virus (HBV) replication. Among them, β -L-2 ′ -deoxythymidine (LdT) or telbivudine (Sebivo®, Novartis Pharmaceuticals, Basel, Switzerland) had the most potent, selective and specific activity against HBV replication, and was selected as an attractive clinical development candidate for the treatment of chronic HBV infection, a worldwide and significant cause of liver-related morbidity and mortality.
Zitieren
APA
Gosselin, G. (2014). Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B. HAMDAN MEDICAL JOURNAL. https://doi.org/10.7707/hmj.401
Vancouver
Gosselin G. Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B. HAMDAN MEDICAL JOURNAL. 2014. doi:10.7707/hmj.401
BibTeX
@article{Gosselin2014,
author = {Gosselin, Gilles},
title = {Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B},
journal = {HAMDAN MEDICAL JOURNAL},
year = {2014},
doi = {10.7707/hmj.401}
}
EUVIMED